Markets:

Overview

News

Currencies

International

Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

48.01 +2.87 (+6.36%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why Shares of Crinetics Pharmaceuticals Are Jumping Monday ↗

September 11, 2023

The biotech company reported positive phase 3 trial results.

Via The Motley Fool

Gold Edges Higher; Virco Manufacturing Shares Surge After Q2 Results ↗

September 11, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 80 points on Monday. The Dow traded up 0.40% to 34,715.88 while the NASDAQ rose 0.58% to 13,841.50. The S&P...

Via Benzinga

Topics Stocks

Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Near the Top of Equities by Percentage Gain on 9/11

September 11, 2023

Via Investor Brand Network

Crinetics Pharma's Investigational Candidate Shows Promise In Rare Type Of Hormonal Disorder ↗

September 11, 2023

On Sunday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) said its Phase 3 PATHFNDR-1 study evaluating paltusotine met the primary and secondary

Via Benzinga

Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 71% ↗

September 11, 2023

The company is working on a treatment for a growth hormone disorder.

Via Investor's Business Daily

US Stocks Open Higher; Dow Jumps 150 Points ↗

September 11, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.46% to 34,736.26 while the NASDAQ rose 0.94% to...

Via Benzinga

Topics Stocks

9 Analysts Have This to Say About Crinetics Pharmaceuticals ↗

August 31, 2023

Via Benzinga

Analyst Expectations for Crinetics Pharmaceuticals's Future ↗

August 09, 2023

Via Benzinga

Why Is Nuwellis (NUWE) Stock Down Today? ↗

September 11, 2023

Nuwellis (NUWE) stock is taking a beating on Monday despite a lack of news or increased trading activity for the medical device company.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 11, 2023

Via Benzinga

Why Is Tenon Medical (TNON) Stock Down 30% Today? ↗

September 11, 2023

Tenon Medical (TNON) stock is falling on Monday after the surgical implant company announced a proposed public offering for its shares.

Via InvestorPlace

Why Is Versus Systems (VS) Stock Up 17% Today? ↗

September 11, 2023

Versus Systems (VS) stock is rising higher on Monday as the business software company's shares experience heavy trading this morning.

Via InvestorPlace

Why Tenon Medical Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket ↗

September 11, 2023

Gainers

Via Benzinga

Where Crinetics Pharmaceuticals Stands With Analysts ↗

June 08, 2023

Via Benzinga

The Latest Analyst Ratings for Crinetics Pharmaceuticals ↗

April 24, 2023

Via Benzinga

Why Is Crinetics Pharmaceuticals (CRNX) Stock Up 64% Today? ↗

September 11, 2023

Crinetics Pharmaceuticals (CRNX) stock is on the rise Monday after the company announced positive clinical trial results.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

September 11, 2023

We're starting off the workweek right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

Via InvestorPlace

Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

September 11, 2023

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

September 10, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment, Says Analyst ↗

August 31, 2023

Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023 ↗

August 31, 2023

Via Benzinga

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 08, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

June 21, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics to Highlight Broad Pipeline at ENDO 2023

June 09, 2023

Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 04, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗

April 24, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗

March 30, 2023

Via Benzinga

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 28, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

February 10, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

All News about Crinetics Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today